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Abstract: Material is reviewed that consists of reconstituted collagen fibril gel mineralized in a manner
that produces biomimetically sized nanoapatites intimately associated with the fibrils. This gel is
formed into usable shapes with a modulus and strength that allow it to be surgically press fitted
into bony defects. The design paradigm for the material is that the nanoapatites will dissolve into
soluble Ca2+ as the collagen is degraded into RGD-containing peptide fragments due to osteoclastic
action. This is intended to signal to the osteoclasts to continue removing the material in a biomimetic
fashion similar to bony remodeling. Preliminary experiments in a subcutaneous rat model show that
the material is biocompatible with respect to inflammatory and immunogenic responses, and that it
supports cellular invasion. Preliminary experiments in a critical-sized mandibular defect in rats show
that the material is resorbable and functions well as a bone morphogenetic 2 (BMP-2) carrier. We have
produced a range of mechanical and biological responses by varying mechanical and chemical
processing of the material.
Keywords: biomaterial; bone substitute; collagen; mineral; resorbable; load bearing
1. Introduction
The ideal solution for reconstructing large bony defects when mechanical strength and stiffness are
required is to transfer autogenous vascularized bone flaps using micro-vascular techniques. However,
microvascular reconstruction is a large clinical undertaking with the potential for significant risk
and donor site morbidity and is inappropriate for the majority of bone defect repair. Autogenous
non-vascularized cortical bone grafting (for structural support) is less demanding and risky but is of
limited supply and still involves some donor site morbidity. These grafts provide functional needs and
are non-immunogenic, but since there is no blood supply and recipient blood vessels are unable to
penetrate the dense cortex, most osteocytes do not survive the implantation. This results in necrosis of
large parts of the graft [1,2]. Alternatively, freeze dried allograft cortical bone from a non-living donor
Materials 2018, 11, 1556; doi:10.3390/ma11091556 www.mdpi.com/journal/materials
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can provide some function [3]. However, this material requires treatment to reduce the likelihood of
an immunological reaction or disease transmission. This treatment reduces biological activity, and like
autogenous grafts, cadaveric bone grafts are often not substantially remodeled. Demineralized bone
matrix (DBM) is devoid of mechanical properties and does not always elicit a favorable biological
reaction [4–6]. Other issues with allografts include limited supply; erratic performance, perhaps due to
varying processing techniques and donor age [5,7,8]; and the risk, albeit small, of disease transmission.
Several synthetic bone substitutes are available but have various deficiencies. Titanium, an effective
material for some craniofacial defects, is well tolerated by the body and can support a load. However,
it is best used in combination with other material such as autogenous grafts or flaps. When used alone
to bridge a defect, particularly in a load-bearing site, the risks of infection, extrusion, fracture, and other
complications (e.g., stress shielding) exist as long as the material remains in vivo. Ceramics and
bioactive glasses can be effective bony in-fill materials but suffer from several limitations. For instance,
it is a matter of debate as to whether sintered hydroxyapatites (HA) are significantly resorbed at
all [9–13], and tricalcium phosphate resorbs too quickly to allow for coupled bone formation [11].
The difficulty in reproducing the physiologic and mechanical behavior of bone is related to the
complex interactions between bone matrix components and the surrounding cellular and soluble
molecule milieu. Mechanically, bone’s structural interdependence on inorganic and organic phases
at the molecular scale allows a range of stiffness, strength, and toughness that is uncommon for
materials with such high mineral content [14,15]. Mechanical models of bone demonstrate the essential
role of nanoscale mineralites with a specific orientation relative to the collagen matrix to achieve the
mechanical properties of bone [16,17]. The 3D geometry of bone substitute materials is important [18].
This notion is presented to contrast our approach with others that focus more on duplicating the
chemical constituents of bone (mainly apatite and collagen) without much focus on the nanoscale
geometry of the constructed composites.
Multiple strategies exist in the literature seeking to produce a biomimetic bone substitute where
nano-scale apatites are intimately interdigitated within and among collagen fibrils. Gower et al. have
been working toward the use of a process they coined “polymer induced liquid polymerization” or
PILP [19] that has been applied to mineralization of collagen fibrils [20] for over a decade now [21].
Another group in Japan has been working almost as long to simultaneously mineralize collagen
fibrils while they are being reconstituted [22]. This material is then isostatically pressed into usable
shapes [23–26]. Our group has also been working on mineralizing collagen fibrils [26], although
our approach involves allowing the fibrillogenesis to complete before mineralization begins [27].
We then use a constant composition system [28] in an attempt to drive mineralization beyond the levels
easily obtainable by simply raising the pH of calcium phosphate solution above its saturation limit.
This technique involves using two solutions: one with CaCl2 and NaCl, the other with K2HPO4 and
NaHCO3. The solutions are placed in separate burettes, which are dispensed via a computer controlled
automated titrator. The system utilizes pH as the control parameter. As apatitic mineralites form,
basic carbonate groups become incorporated in the mineral precipitating out of solution, resulting in a
drop in pH. By detecting small drops (~0.003 units) in pH and then simultaneously releasing the two
solutions in a controlled ratio, the ionic concentration is kept constant, thus maintaining a constant
molar composition of the reactants.
Design of a bone substitute requires balancing mechanical and biological (osteointegrative)
properties. To create a material using biological molecules that has sufficient mechanical strength to
function in load bearing applications, the material must be densified. This is done at the expense of
porosity, thus impeding osteointegration. A central assumption of our design is that replicating key
structural features of bone on a nanoscale relaxes the microscale pore size requirements necessary
for osteointegration compared with currently used bone substitute materials. Our preliminary data
suggests this is true. A putative mechanism for this result involves activating a cellular remodeling
process, as opposed to a chronic inflammatory reaction, thus initiating a primary bone healing
mechanism within the implant. It is thus hypothesized that by constructing this bone substitute
Materials 2018, 11, 1556 3 of 16
material as a biomimetic composite, the material will have the potential to function clinically as
an off-the-shelf bone implant. Importantly, the implant is designed with the intent of being used to
reconstruct some types of defects in aspects of the skeleton that have load-bearing function. Biologically,
there is evidence in the presented work that it is replaced with normal lamellar bone in rats, providing
justification for further preclinical trials in larger animals.
What follows is a review of work we have previously published on the development and behavior
of this material, along with some new data on its in vitro characterization. This is the first time we
have presented the full nanoscale biomimetic design rationale for the material. In addition, it is the
first time we have presented the physico-chemical, in vitro, and in vivo results in one place.
2. Material Designed around Interaction with Osteoclasts
Our goal is to produce a bone substitute material mechanically robust enough to provide
load-sharing, if not load-bearing, structural support in the defect volume while still being resorbable.
Rather than resorption via simple hydrolysis (as occurs in polylactic acid/polyglycolic acid, PLA/PGA,
and tricalcium phaosphate, TCP, materials), we aim to have the material removed via osteoclast
acitivity at a rate driven by the normal bone-healing process, much like how normal bone-turnover
occurs during remodeling. Past work shows that osteoclasts possess membrane-bound receptors
optimized for sensing soluble calcium and RGD containing denatured collagen fragments [29–31].
These receptors are hypothesized to act in shutting down the resorption activity of the osteoclast [32–34].
If this happens too quickly, the biomaterial will not be resorbed. If it happens too slowly, the biomaterial
will be removed too quickly for subsequent osteoblastic activity to fill in the resorption vacuole. Thus,
biomimetic material must decompose during osteoclastic resorption in a manner that increases the
local calcium and denatured collagen concentrations at a rate similar to bone. Local lowering of
extracellular pH by osteoclasts provides a physical mechanism for dissolving apatite. However, it has
been shown that the nanoapatites in bone will dissolve and reprecipitate even near neutral pH once
they are removed from their collagen matrix [30,33,35,36]. Thus, it is possible that natural rises in
[Ca2+] during remodeling come from a combination of lowered pH and destruction of the protective
collagen fibril matrix surrounding the nanoapatites. Our central paradigm for biomaterial synthesis is
that the rate of release of collagen fragments and Ca2+ ions is controlled by the composite structure of
the mineralized collagen fibril in bone. The phases of interest in this composite are the bone apatite
and the collagen. The apatite may be found as nanomineralites within the collagen fibril, on the fibril
surface, or as larger mineral pieces not directly associated with a fibril (Figure 1). Mimicking the
portion of this structure involving nanoapatites directly associated with collagen fibrils thus becomes
essential in producing a biomaterial that will be remodeled like the native bone surrounding it. If this
mineralized fibril can be duplicated, then osteoclastic action is expected to produce soluble calcium
and RGD-containing collagen fragments at a biomimetic rate. Based on the argument above, these
components, presented to the osteoclastic ruffled border at the proper ratio, will drive the osteoclast to
continue resorbing the synthetic bone.
Obtaining 10 nm sized mineralites and interspersing them with <100 nm spacing within a collagen
matrix is difficult. We have accomplished this task by constructing a template for mineralization
utilizing the natural self-assembling properties of collagen molecules [26]. The resulting structure
has the same molecular arrangement as bone on a <1 µm length scale and possesses 1–10 nm sized
void spaces of two shapes: short and thick, long and thin. We fill these voids with solid mineral by
thermodynamically driving soluble Ca2+, PO4−, and CO3− ions to nucleate inside the collagen fibrils
and grow into mineralites.
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calf skin collagen. Briefly, a solution of lightly pepsin digested and acid solubilized collagen 
monomer (3 mg/mL PureCol, Advanced BioMatrix, San Diego, CA, USA) at 4 °C was diluted to 0.2 
mg/mL in a TES buffer (Fisher Scientific, Hampton, NH, USA) containing 140 mMol NaCl and 1 
mMol potassium phosphate at 37 °C and pH 7.4. After 24 h of incubation at 37 °C, fibril gels were 
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were rinsed in ethanol, stocked into a cylindrical bore uniaxial press and compressed under either 35 
kPa or 350 kPa for 24 h. These samples are referred to as uniaxially pressed (UP) below. 
4. In Vitro Material Characterization 
4.1. Sub-µm Structure and Chemistry of Our Material 
Our design requires that the monomers assemble into a D-staggered array [42] containing 40 nm 
gaps between the amino and carboxy termini of adjacent collagen monomers. Figure 2 shows our 
synthesis procedure results in such a structure. At lower magnification, scanning electron microscopy 
shows these banded fibrils have diameters of 75 nm ± 5 (N = 70) (unless otherwise stated, all ± values 
represent the 95% confidence intervals for stated parameters). As seen in Figure 3, the fibrils are 
entangled with each other. When hydrated, they constitute a loose hydrogel with a density that 
appears homogeneous to the unaided eye. After mineralizing in a supersaturated solution containing 
carbonate and phosphate, SEM shows aggregated objects around a micron in size. Energy dispersive 
X-ray analysis is consistent with these aggregates being apatites; they have Ca/P ratios in the normal 
bone range of 1.4 to 1.8. Mineral deposits within the gap zones of the D-staggered array would not 
be visible using SEM. To examine these very small mineralites, we performed a hydrazine extraction 
and examined the resulting powder using X-ray diffraction to qualitatively assess the crystal 
perfection as well crystallite size. While intensity characteristics of apatites at angles around 27°, 
30.5°, −33.5°, and 40° were observed, no triplet peaks (211, 112, 300) were observed, suggesting that 
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4. In Vitro aterial Characterization
4.1. Sub-µm Structure and Chemistry of Our Material
Our design requires that the monomers assemble into a D-staggered array [42] containing 40 nm
gaps between the amino and carboxy termini of adjacent collagen monomers. Figure 2 shows our
synthesis procedure results in such a structure. At lower magnification, scanning electron microscopy
shows these banded fibrils have diameters of 75 nm ± 5 (N = 70) (unless otherwise stated, all ± values
represent the 95% confidence intervals for stated parameters). As seen in Figure 3, the fibrils are
entangled with each other. When hydrated, they constitute a loose hydrogel with a density that
appears homogeneous to the unaided eye. After mineralizing in a supersaturated solution containing
carbonate and phosphate, SEM shows aggregated objects around a micron in size. Energy dispersive
X-ray analysis is consistent with these aggregates being apatites; they have Ca/P ratios in the normal
bone range of 1.4 to 1.8. Mineral deposits within the gap zones of the D-staggered array would not be
visible using SEM. To examine these very small mineralites, we performed a hydrazine extraction and
examined the resulting powder using X-ray diffraction to qualitatively assess the crystal perfection
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as well crystallite size. While intensity characteristics of apatites at angles around 27◦, 30.5◦, −33.5◦,
and 40◦ were observed, no triplet peaks (211, 112, 300) were observed, suggesting that the apatites
were very small (Figure 4). While generally the X-ray diffractogram looked very similar to young
bovine bone, one can easily differentiate that both the synthetic and natural mineralites differ from
sintered HA. The Sintered HA typically has highly crystalline hydroxyapatite and larger crystal size,
in which triplet peaks are observed between 30.5 and 33.5 degrees (2 theta). The synthetic apatites
have a slightly sharper/taller 002 peak than the natural mineralites. While the mineral/grain sizes
are comparable (based on broadening of the 211, 112, and 300 peaks), it is possible that natural bone
mineralites have more crystal imperfections such as substitution ions (Na for Ca and Cl for OH),
which produce a weaker 002 peak. Collection of multiple XRD patterns would allow us to further
characterize the diffraction behavior by providing an average and standard deviation of the 002 peak.
In addition, chemical analysis and solubility product (Ksp) may help establish these subtle differences
in future research.
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image using transmission electron microscopy. The high frequency pattern indicated by the arrows
is a typical sub-banding pattern seen with this preparation. hen four of these bands are averaged,
a repeat of 67± 4 nm is found. The presence of the banding indicates that our fabrication process results
in fibrils with ~40 nm gaps between molecules, which are available for subsequent mineralization.
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Figure 3. Scanning electron micrographs of our collagen gels before (left) and after (right)
mineralization. Average fibril diameters show a mean of 75 ± 21 nm (N = 70). After mineralization,
micron size aggregates are visibly trapped in the gel (indicated by arrow in right panel). Energy
dispersive X-ray analysis (EDX) shows Ca and P in a ratio of ~1.8 present in these aggregates. On regions
of the surface with no apparent aggregates (ex. inside the dashed circle near the middle of the right
panel), EDX shows Ca/P ∼= 1.4.
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Figure 4. X-ray diffractogram showing synthetic mineral extracted from our material is crystallographically
similar to mineral from bovine bone.
To visualize individual mineralites within the powder, we used atomic force microscopy (Figure 5).
While there were a few (<1%) objects >100 nm in size, the great majority of mineralites had mean
dimensions of 8 × 6 × 2.5 nm. These dimensions were similar to those previously measured for
young bovine bone [37] with the natural and synthetic dimensions overlapping within one standard
deviation (n > 200). While mineralites of this size and shape would likely fit into the gap zones inside
an assembled collagen fibril, it is not clear at this point if the mineral exists predominately on the
surface of the fibrils or if it is also in the interior of the fibril. Tomographic TEM would be able to
resolve this issue [43,44].
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Figure 5. Atomic force microscopy was used to measure the size and shape of natural and synthetic
mineralites. Panel at upper left sho s top down view of hydrazine-extracted synthetic mineralites
deposited on mica. A line scan through the mineralite indicated with the arrow is shown at lower left.
The means and standard deviations of mineralites from 1–3 month old cows (n = 238) and synthetic
mineralites (n = 202) are shown at lo er right. The upper right image sho s a 3D view of the mineralite
indic ted with the arrow in the upper left panel. This 3D image was typical of both natural and
synthetic mineralites.
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4.2. BMP-2 Release
We looked at the release of BMP-2 from our material incorporating the growth factor in two
different ways: [38] (1) We put the BMP-2 into solution during fibrillogenesis (group A); (2) After
fibrillogenesis was complete, we immersed the material in a solution containing BMP-2 (group B).
Both treatments exposed the material to the same concentration of BMP-2 for the same period of time.
Three samples of each treatment were tested. Over the next three days, the material was immersed in
DI water, which was exchanged for fresh water 15 times. Just prior to each exchange, we extracted two
aliquots and tested for BMP-2 using an ELISA assay. After the first four washes (~12 h), there was no
further significant release of BMP-2 from group B materials. Group A materials showed significant
BMP-2 release after 10 washes. Thus, incorporating BMP-2 during fibrillogenesis appears to cause a
slower release compared to incorporation after collagen fibrils are formed.
For both treatments, the last three measurements showed that the BMP-2 concentration had
dropped below the detectable limit of the assay. Thus, any BMP-2 left in the material was not able
to be released by simple diffusion. We then treated the material with collagenase, causing complete
material degradation. After collagenase treatment, the BMP-2 signal increased for both treatment
groups. However, it spiked back up only to the level of the first fluid exchange for the group B samples.
Group A samples spiked >5× higher than the original concentration. This is very encouraging and
suggests that incorporating BMP-2 during fibrillogenesis may allow for substantial reductions in the
amount of growth factor needed in vivo. In addition, incorporation during fibrillogenesis may provide
for a more sustained release kinetic, resulting in a more favorable physiological response needed to
ensure the implant material is completely resorbed and replaced by bone as clinically required.
4.3. Cellular Response
A co-culture of mesenchymal support cells (ST2 from the Riken cell bank) and hematopoietic
progenitor cells from young mouse spleens (all animal studies were performed in accordance with the
Institutional Animal Care and Use Committee (IACUC), Case Western Reserve University) was used
to obtain an osteoblast/osteoclast population on our material [45,46]. Cells were also plated on a few
samples of elephant ivory as a positive control for osteoclast formation and activation. We routinely
saw resorption features on the ivory similar to those previously reported [47]. Cultures were performed
three separate times on three different sets of substrates. The duration of the culture was 10 days.
In every case, the ST2 cells adhered and grew to confluence on our material. In addition, the mouse
spleen cells stained positive for tartrate-resistant acid phosphatase (TRAP) and were present as
multinucleated cells. We compared the behavior of these osteoclasts on our material with their
behavior on unmineralized collagen gels and sintered hydroxyapatite. We looked for resorption pits
like those shown in Figure 6. More than 300 randomly chosen fields of view were collected with
SEM on each sample type. Pits were counted by eye using a blinded set of files (i.e., the counter
did not know from which sample the image under study was collected). Three criteria were used
to identify a region of interest as a resorption feature. First, the feature in question was to be 3/4
or more surrounded by a border (a step change in contrast). Second, the bordered area was to be
at least 10 µm in its longest dimension. Third, the surface roughness (as measured by the standard
deviation of the histogram of image intensity levels) within that border was to be 40% greater than
the local surface outside the border. The same size region was used to evaluate the histogram inside
the border and on the background adjacent to the border. The 40% threshold was chosen, because the
background never varied more than 40% from spot to spot. We expect that the increase in roughness
within a resorption feature was the result of collagen fibril disruption during the resorption process.
The number of resorption pits per osteoclast on our material was >2× higher than on either the
unmineralized collagen or the sintered hydroxyapatite. This finding encouraged us to move on to
small animal studies.
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pits are indicated ith arro s. These features ere seen only after cell culture.
The material tested in vitro was an unpressed gel. We were able to substantially densify the gel by
mechanical pressing alone. The mechanical properties of this pressed material are sufficient for press
fitting samples into custom made defects in bone. However, the samples are not strong enough to hold
a screw and they do show substantial loss in stiffness when immersed in water for 30 min. We found
that crosslinking the pressed samples allowed them to hold a screw and reduced the loss of mechanical
properties upon hydration. Thus, when we moved on to in vivo testing, we used crosslinking as one
of our test variables.
5. In Vivo Testing
Using a subcutaneous rat model, a study was done with four objectives [39]: first, to establish
biocompatibility with respect to immune and inflammatory responses; second, to study the
host-material interface as a function of pore size and crosslinking; third, to assess cellular penetration
as a function of pore size and crosslinking; and fourth, to compare glycation (D-ribose) and dialdehyde
(glyoxal) mediated crosslinking. Glycation mediated crosslinking is found in biological systems
and has been studied specifically with respect to collagen [48], whereas dialdehydes are toxic in the
unbound state. Seven variations of the material, created by varying the degrees of densification and
crosslinking, were tested. A two week time course was used to evaluate the tissue reaction after
the acute phase of inflammation had been largely resolved (based on a pilot study) but before any
significant material degradation had occurred. Parameters studied included gross morphological
features, as well as semi-quantitative histological measures. Histological evaluation was performed by
two blinded graders. Foreign body giant cells (FBGC) were counted per high powered field of view
in four different fields and averaged. The host-biomaterial interface was assessed by the degree of
fibrous encapsulation, which was graded on a scale of 0–4 (measuring the degree of encapsulation
and integration of host tissues with the substance of the material) and cellular penetration that was
quantified by assessing how far into the material cells had penetrated. All materials were tested in
each of 12 rats that necessitated paired statistics. The Wilcoxon signed rank test was used to detect a
difference between groups.
In each rat, all materials were well tolerated. There was no evidence of gross inflammation,
infection, or extrusion. Histologically, the acute inflammatory phase had mostly resolved in all
samples, as indicated by the relatively small numbers of polymorphonuclear cells, and there was
little evidence of chronic inflammation. FBGC were more ubiquitous in non-crosslinked samples
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than crosslinked samples. This appears to be a function of material degradation, since a collagen
sponge (employed as a control) elicited the highest numbers of FBGC, though without any gross
inflammation. In non-crosslinked samples, the material/tissue interface was ill-defined with fibroblasts
and likely endothelial cells infiltrating into the bulk of the material (Figure 7) as opposed to crosslinked
samples, which caused the formation of a dense and poorly adherent fibrous capsule. Pore size
in uncrosslinked samples did not significantly impact the host-material interface using any of the
tested metrics. The crosslinked samples had significantly less cellular penetration and soft tissue
integration than uncrosslinked samples. Crosslinking time (presumably related to crosslinking density)
correlated with degree of fibrous encapsulation and cellular penetration. These results indicated that
smaller pore volumes did not negatively impact the biological interface. It further showed that the
heavy crosslinking, though effective at stabilizing material constructs, tended to negatively impact
the biological interface. Since there was no significant difference between D-ribose and glyoxal with
respect to construct stability, D-ribose is exclusively used to crosslink our samples.
Materials 2018, 11, x FOR PEER REVIEW  9 of 16 
 
i fla ati . In on-crosslinked samples, the material/tissue interface was ill-defined with 
fibroblasts and likely endothelial cells infiltrating into the bulk of the material (Figure 7) as oppose  
to crosslinked samples, w ich caused the formation of a dense nd poorly adherent fibrous capsule. 
Pore size in uncrosslink d samples did not significantly impact the host-material interface using any 
of the tested metrics. The crosslinked samples had significantly less cellular penetration and soft 
tissue integration than uncrosslinked samples. Crosslinking time (presumably related to crossli king 
density) correlat d with degree of fibrous e capsulation and cellular pen tration. These results 
indicated that smaller pore volumes did not negatively impact the biological interface. It further 
showed that the heavy crosslinking, though effective at stabilizing material c nstructs, tended to 
negatively impact the biological interface. Since there was no significant differenc  between D-ribose 
and glyoxal with respect to construct stability, D-ribos  is exclusively used to crosslink our samples. 
 
Figure 7. Histological evaluation using an H&E stain of two different preparations of the material. 
(A) non-crosslinked sample. Note the tight adherences of the host tissue with the implant (arrows). 
While there is evidence of the rudiments a fibrous capsule, the border between host tissue and implant 
is poorly demarcated. There is a column of fibroblasts and possibly endothelial cells infiltrating into 
the substance of the implant (arrow heads) 10×. (B) a crosslinked sample. Note that there is a well-
formed fibrous capsule commonly seen with crosslinked samples (arrows). The capsule did not 
tightly adhere to the sample, and there was minimal cellular infiltrate 4×. 
6. Rational for the Rodent Mandibular Model 
The importance of small animal studies in the investigation of bone substitute materials is well 
documented [49,50]. Our study involved manipulation of craniofacial tissue on a minimal level. 
Primitive responses of bone to basic functional craniofacial skeletal manipulations are shared by all 
mammals. Therefore, the rat, as a generic animal model, is appropriate for our level of hypothesis 
testing [51,52]. Mature males were used, because their size facilitated surgical manipulation of the 
mandible.  
The mandibular critical size defect (CSD) lends itself to testing load-bearing bone substitutes. A 
critical size defect (>5 mm × 5 mm) is made through robust bone in the body of the mandible. Previous 
reports suggest the bone near the angle of the mandible is thin, making implant placement and 
immobilization difficult [49]. We find placing the defect more anterior (rostral) in the mandibular 
ramus so the anterior extent of the defect lies just postero-inferior to the incisor root allows the defect 
to be readily extended to 6 mm × 6 mm and beyond while leaving intact surrounding bone that is 
strong enough to hold an implant firmly in place (Figure 8). This is done without adversely affecting 
the root of the incisor. When placed in this fashion, rats tolerate the surgery well with no ill-effect to 
their dentition or eating habits by postoperative day 3 (n > 30). This defect does not significantly 
remodel when left unfilled, which has been cited as a concern in other reports (Figure 9) [49]. The 
implant is fixed in the defect by creating a precise size match between the implant and defect. 
Effective fixation of the implant has been demonstrated multiple times by μCT and explantation. 
i . i t l i l l ti i t i f t iff t ti s f t t i l.
. t f i l t ).
il fi
rl de arcated. There is a column of fibroblast and possibly endothelial cells infiltrating i to the
substance of the implant (arrow heads) 10×. (B) a crosslinked sample. Not that there is a well-formed
fibrous capsule commonly seen with crosslinked samples (arrows). The capsule did not tightly a here
o the s mple, and there was minimal cellular filtrate 4×.
6. ati al f r t e e t a i lar el
e i rta ce f s all a i al st ies i t e i esti ati f e s stit te aterials is ell
c e te [49,50]. ur study i volved anipulation of craniofacial tissue on a i i al le el.
ri iti e res ses f e t asic f cti al cra i facial s eletal a i lati s are s are all
a als. eref re, t e rat, as a e eric a i al el, is a r riate f r r le el f t esis
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e a ib lar critical size defect (CSD) lends itself to testing load-bearing bone substitutes.
A critical size defect (>5 mm × 5 m ) is made through robust bone in the body of the mandible.
Previous reports suggest the bone near the angle of the mandible is thin, making implant placement
and immobilization difficult [49]. We find placing the defect more anterior (rostral) in the an ib lar
ra us so the anterior extent of the defect lies just postero-inferior to the incisor root allows the defect to
be readily extended to 6 mm × 6 mm and beyond while leaving intact surrounding bone that is strong
enough to hold an implant firmly in place (Figure 8). This is done without adversely affecting the
root of the incisor. When placed in this fashion, rats tolerate the surgery well ith no ill-effect to their
dentition or eating habits by postoperative day 3 (n > 30). This defect does not significantly remodel
when left unfilled, which has been cited as a concern in other reports (Figure 9) [49]. The implant is
fixed in the defect by creating a precise size match between the implant and defect. Effective fixation
of the implant has been demonstrated multiple times by µCT and explantation.
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studies exist saying that it is safe and efficacious [59], other studies point out its limitations [60,61]. 
Based on current clinical best practices, the concentration of BMP-2 needed to achieve a useful 
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fixed and well stabilized with solid cortical bone superiorly, anteriorly, and posteriorly. The implant is
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Materials 2018, 11, x FOR PEER REVIEW  10 of 16 
 
 
Figure 8. The nanocomposite is implanted in a CSD in the left mandibular body. The material is 
solidly fixed and well stabilized with solid cortical bone superiorly, anteriorly, and posteriorly. The 
implant is not easily dislodged on manual palpation. 
 
Figure 9. Explanted mandible (dissected free of soft tissue) of a control animal (no implantation) at 
the conclusion of an 8 week study. ON the left is a left hemimandible following the creation of an 
unimplanted critical size defect (arrow). On the right is the unoperated contralateral side. 
7. Nanocomposite Material as a Bone Substitute and Drug Delivery Vehicle 
Based on our experience, as well as a review of the literature, a scaffold material alone, even with 
good osteoconductive properties, will not likely function as an optimal bone substitute without the 
addition of bioactive factors. This conclusion was confirmed in our material after several renditions 
were studied using the rat mandible model without the addition of any bioactive factors. Each 
material was tested in pilot studies with 3 animals per group. 
Non-crosslinked samples were resorbed in 8 weeks and appeared to contribute to some skeletal 
remodeling. However, these samples did not show evidence of osteoinductivity, and the defects were 
not completely bridged even after all material was fully resorbed. Heavily crosslinked samples were 
not significantly resorbed. Histologically, a fibrous capsule formed between the material and bone, 
indicating a fibrous non-union. 
Based on these findings, materials were doped with BMP-2. Previous studies showed favorable 
pharmacokinetics when BMP-2 was used in collagen-based delivery systems [53]. It is not ideal to 
release high levels of BMP-2 in one initial bolus, as this can result in abnormal bone formation such 
as a peripheral “bone shell” [54–56]. Collagen carriers are associated with sustained release of BMP-
2 in contrast to mineral based carriers, which show a high initial release that tapers quickly [57]. 
Furthermore, ceramics and dehydrated bone can alter the chemical structure of released growth 
factors [58]. In contrast, BMP-2 binds to collagen sponges without compromising activity, and protein 
incorporation into the collagen carrier can be modulated by changing material fabrication parameters 
[53]. 
It is worth noting that the clinical literature is divided on the wisdom of using BMP-2. While 
studies exist saying that it is safe and efficacious [59], other studies point out its limitations [60,61]. 
Based on current clinical best practices, the concentration of BMP-2 needed to achieve a useful 
response is much higher than the naturally occurring concentration of BMP-2. This raises concerns 
about carcinogenicity. In addition, there are important site-specific dosing concerns regarding ectopic 
bone formation and neurological complications that make it necessary to test a product in each 
location of its intended use. This can be costly and delay time to market for new products using this 
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7. Nanocomposite Material as a Bone Substitute and Drug Delivery Vehicle
Based on our experience, as well as a review of the literature, a scaffold material alone, even with
good osteoconductive properties, will not likely function as an optimal bone substitute without the
addition of bioactive factors. This conclusion was confirmed in our material after several renditions
were studied using the rat mandible model without the addition of any bioactive factors. Each material
was tested in pilot studies with 3 animals per group.
Non-crosslinked samples were resorbed in 8 weeks and appeared to contribute to some skeletal
remodeling. However, these samples did not show evidence of osteoinductivity, and the defects were
not completely bridged even after all material was fully resorbed. Heavily crosslinked samples were
not significantly resorbed. Histologically, a fibrous capsule formed between the material and bone,
indicating a fibrous non-union.
Based on these findings, materials were doped with BMP-2. Previous studies showed favorable
pharmacokinetics when BMP-2 was used in collagen-based delivery systems [53]. It is not ideal
to release high levels of BMP-2 in one initial bolus, as this can result in abnormal bone formation
such as a peripheral “bone shell” [54–56]. Collagen carriers are associated with sustained release
of BMP-2 in contrast to mineral based carriers, which show a high initial release that tapers
quickly [57]. Furthermore, ceramics and dehydrated bone can alter the chemical structure of released
growth factors [58]. In contrast, BMP-2 binds to collagen sponges without compromising activity,
and protein incorporation into the collagen carrier can be modulated by changing material fabrication
parameters [53].
It is worth noting that the clinical literature is divided on the wisdom of using BMP-2. While
studies exist saying that it is safe and efficacious [59], other studies point out its limitations [60,61].
Based on current clinical best practices, the concentration of BMP-2 needed to achieve a useful
response is much higher than the naturally occurring concentration of BMP-2. This raises concerns
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about carcinogenicity. In addition, there are important site-specific dosing concerns regarding ectopic
bone formation and neurological complications that make it necessary to test a product in each location
of its intended use. This can be costly and delay time to market for new products using this growth
factor. Recognizing these complexities, we moved forward to test our material as a BMP-2 carrier.
In a study evaluating our material combined with BMP-2, non-crosslinked samples were tested
by applying a bolus of 3 µg BMP-2 in 30 µL DI water directly to the implant 15 min prior to
implantation (allowing absorption by capillary action). This dosage was based on prior studies
in the rat mandible [62]. The method of dosing the materials with BMP-2 was intended to mimic
the clinically used process associated with Medtronic’s InfuseTM product. In an 8-week study,
the samples exhibited good osteointegration with excellent spanning of the defect with hard callus
(Figure 10). Mechanical strength and stiffness of the implanted hemimandibles closely approximated
the contralateral unoperated side. Histologically, the material showed no significant evidence of a
foreign body reaction. Complete osteointegration with no discernable border between implant and
native bone was seen (Figure 11). In addition, there was clear evidence of active bone remodeling
within the implant (Figure 12) [63]. Some organized fibrous tissue at the core of the implant was
presumably an area not infiltrated by the BMP-2. In contrast, heavily crosslinked samples exhibited
poor osteointegration. This is likely related to poor diffusion of the BMP into the denser material,
as well as poor biological properties associated with crosslinking. These results demonstrate three
important points. First, the subcutaneous model was predictive of the bony model with respect to
material-host interface and material stability. Second, the material is an effective carrier for BMP-2
when the protein is properly absorbed into the material. Finally, the material needs some degree of
crosslinking to confer necessary mechanical properties, yet high levels of crosslinking interfere with
BMP-2 uptake and therefore osteointegration.
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materials can be enhanced in crosslinked samples by taking advantage of scaffold architecture. Aside 
from chemical interaction, another mechanism for preserving the protein in a carrier and releasing it 
in delayed fashion is physical hindrance [53,64,65]. Given the spatial dimensions of the BMP-2 
molecule [66], a steric interdigitation of the molecule into the gap zones between collagen monomers 
of the collagen fibril appears to be feasible. This can be done during fibrillogenesis. This theory 
assumes that BMP release will be controlled by in vivo enzymatic scaffold degradation as part of the 
bone healing response. By combining the nanoscale 3D architecture of the collagen/mineral bone 
fibril with steric interdigitation of BMP-2, densification, and mild crosslinking, we have evidence to 
suggest that we can produce a new bone substitute material that resists moderate compressive, shear, 
and tensile forces while activating new bone formation. There is no comparable material currently 
available for clinical skeletal reconstruction. 
Figure 10. Explanted left hemimandibles (with soft tissue attached) in the experimental groups at
the conclusion of an 8 week study. (A) Undoped nanophase composite implanted in the critical size
defect (arrow) and (B) BMP-2 doped nanocomposite implanted in a critical size defect with robust
bony ingrowth (arrow).
Based on the combined results from the previous paragraph and the section above entitled “BMP-2
Release”, we construct the following argument. Effective doping of BMP into scaffold materials can be
enhanced in crosslinked samples by taking advantage of scaffold architecture. Aside from chemical
interaction, another mechanism for preserving the protein in a carrier and releasing it in delayed
fashion is physical hindrance [53,64,65]. Given the spatial dimensions of the BMP-2 molecule [66],
a steric interdigitation of the molecule into the gap zones between collagen monomers of the collagen
fibril appears to be feasible. This can be done during fibrillogenesis. This theory assumes that BMP
release will be controlled by in vivo enzymatic scaffold degradation as part of the bone healing
response. By combining the nanoscale 3D architecture of the collagen/mineral bone fibril with steric
interdigitation of BMP-2, densification, and mild crosslinking, we have evidence to suggest that we
can produce a new bone substitute material that resists moderate compressive, shear, and tensile forces
while activating new bone formation. There is no comparable material currently available for clinical
skeletal reconstruction.
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Figure 11. Histological evaluation of the BMP-2-doped NBS from Figure 10. The non-demineralized
sections are embedded in acrylic and stained with Goldner’s trichrome. Mineralized tissue stains blue.
(A) This coronal µCT section provides orientation for B & C. The black arrows point to the NBS/bone
interface (corresponding to those in (B)) with the implant seen beneath the arrows. The arrow head
indicates the inferior border of the NBS (corresponding to those in (C)). (B) The arrows demonstrate
the location of the original interface between mandible and NBS. Note complete osteointegration of the
NBS and robust bone formation. † The open space is due to a processing artifact (40×). (C) The defect
volume consists primarily of new bone. There remains NBS material in the core (indicated with *),
but the interface between bone and NBS is irregular and marked by active bone remodeling without
fibrous tissue. The area marked with the arrow heads is the free inferior border of the mandible/implant
(20×). This figure presented with permission from Wiley [38].
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Figure 12. Osteoclastic activity (arrow) was noted throughout the bulk of the implant and indicates
normal remodeling of the implant at 8 weeks.
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8. Summary
The nanophase bone substitute (NBS) is a composed of a composite scaffold engineered at the
nanoscale. It is osteointegrative and has the potential for robust mechanical stability in a physiological
environment. Furthermore, the synthesis process can be tailored to encourage biologically induced
bone morphogenetic protein release instead of less regulated physical diffusion. Thus, it can be
used as a carrier of growth/differentiation factors and cytokines, when enhanced osteoinductive
properties are useful. We view the NBS as a platform technology with broad ranging clinical potential.
Its obvious application is in reconstructing traumatic bony defects, as well as those that exist because
of congenital malformation. If used with cytokines or growth factors, it would not be suitable for
post-cancer extirpative reconstruction due to the concern for tumorgenicity. However, we envision a
possible use for the NBS in a post-neoplasm environment when used as a carrier for antineoplastic
agents. The study of the NBS in the rat mandible presented here focused on the craniofacial skeleton.
Ultimately, the goal is to produce a fully bio-degradable bone substitute material that can be used to
reconstruct bony defects in any part of the skeleton that requires initial implant stability before being
replaced by bone.
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Abbreviations
BMP-2 Bone morphogenetic protein 2
Ca/P Calcium/phosphate
CSD Critical size defect
BM Demineralized bone matrix
DI Deionized
EDX Energy dispersive x-ray analysis
ELISA Enzyme-linked immunosorbent assay
FBGC Foreign body giant cell
HA Hydroxyapatite
H&E Hematoxylin and eosin
IACUC Institutional animal care and use committee
NBS Nanophase bone substitute
PLA/PGA Polylactic acid/polyglycolic acid
SEM Scanning electron microscopy
TCP Tricalcium phosphate
TEM Transmission electron microscopy
TRAP Tartrate resistant acid phosphatase
UP Uniaxially pressed
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